1GAAP operating income for fiscal 2025 was -$26.6M, aligned with the company's history of operating losses as a pre-revenue biotechnology firm.
2GAAP net income for fiscal 2025 was -$26.3M, with no product revenue generated from the company's activities to date.
3GAAP diluted earnings per share for fiscal 2025 was $-6.33, reflecting the company's full-year operating loss for the period.
4Free cash flow for fiscal 2025 was -$26.8M, as capital expenditures for the year totaled $0, matching net cash used in operating activities.
5As of December 31, 2025, the company holds no long-term debt and no material non-cancelable purchase commitments with service providers.
6The company anticipates continued losses for the foreseeable future, requiring additional financing to meet its strategic business goals.